2025 Q4 -tulosraportti
43 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 295 004 | 295 004 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 295 004 | 295 004 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6 t sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·4 t sittenKDIGO has some guidelines now. Hospitals treat according to them, and insurance companies compensate. If Ngal is to be included, then I find it hard to see KDIGO moving to a place where there is no evidence! And evidence will probably only come in the adult area when companies deliver studies that FDA approves based on. That's probably what BioPorto is doing - honestly! And still...: If insurance companies are to pay up, then they will probably lean on products that are approved?! An unapproved product probably doesn't have much weight in relation to insurance companies? KDIGO or not! Regards, Bagerbrød
·4 t sittenI have spent hours trying to make sense of KDIGO. I have shared everything further down. If I am right that it becomes a 1st degree recommendation in crisis areas, then all hospitals, including in the USA, will ensure that the NGAL test becomes a permanent part of routine treatments in affected areas. If hospitals in the USA do not introduce the NGAL test where there is a 1st degree recommendation, and deaths occur at this hospital, then they risk being sued by relatives because they did not use the NGAL test, according to KDIGO's recommendations. What the FDA might do, regarding the NGAL test, for adults, after a 1st degree recommendation, and they have not yet approved the test, is to give it emergency use authorization status, while the FDA is in the process of their procedure. With a 2nd degree recommendation, it is up to the doctor's assessment whether they want the NGAL test in their routine treatment.
9 t sitten9 t sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.- ·10 t sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
·3 päivää sitten3D missen can you explain to me why you think this one is so interesting I am very curious good luck·2 päivää sittenI can't remember it exactly, but I was involved when they were still at the research level. four years maybe. why that?·2 päivää sittenNgal has been on the market for approx. 15 years and frankly, Bioporto is still in a form of "research level" and start-up in 2026 without a shadow of PROC.
·4.5.It was just going the right way, and now it's plummeting today??·4.5. · MuokattuWhile I wait for the hearing to end on Monday, It occurred to me whether there have been any articles, from the research, about the NGAL test, that could detect, at an earlier stage, that their kidney is damaged. ( That was their working title ) I found the scientific article that describes what the researchers found out. One can read in the article that the researchers had positive results, and that it looked as if the NGAL test, at an early stage, could detect if the kidney was damaged. When KDIGO comes with their recommendations, and if they include this group, as a 1st degree recommendation, then the test will become a permanent part of the treatment offer. See below, conclusions. https://www.sciencedirect.com/science/article/pii/S1056872725000558
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
43 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·4 t sittenKDIGO has some guidelines now. Hospitals treat according to them, and insurance companies compensate. If Ngal is to be included, then I find it hard to see KDIGO moving to a place where there is no evidence! And evidence will probably only come in the adult area when companies deliver studies that FDA approves based on. That's probably what BioPorto is doing - honestly! And still...: If insurance companies are to pay up, then they will probably lean on products that are approved?! An unapproved product probably doesn't have much weight in relation to insurance companies? KDIGO or not! Regards, Bagerbrød·4 t sittenI have spent hours trying to make sense of KDIGO. I have shared everything further down. If I am right that it becomes a 1st degree recommendation in crisis areas, then all hospitals, including in the USA, will ensure that the NGAL test becomes a permanent part of routine treatments in affected areas. If hospitals in the USA do not introduce the NGAL test where there is a 1st degree recommendation, and deaths occur at this hospital, then they risk being sued by relatives because they did not use the NGAL test, according to KDIGO's recommendations. What the FDA might do, regarding the NGAL test, for adults, after a 1st degree recommendation, and they have not yet approved the test, is to give it emergency use authorization status, while the FDA is in the process of their procedure. With a 2nd degree recommendation, it is up to the doctor's assessment whether they want the NGAL test in their routine treatment.
- 9 t sitten9 t sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.
- ·10 t sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
- ·3 päivää sitten3D missen can you explain to me why you think this one is so interesting I am very curious good luck·2 päivää sittenI can't remember it exactly, but I was involved when they were still at the research level. four years maybe. why that?·2 päivää sittenNgal has been on the market for approx. 15 years and frankly, Bioporto is still in a form of "research level" and start-up in 2026 without a shadow of PROC.
- ·4.5.It was just going the right way, and now it's plummeting today??·4.5. · MuokattuWhile I wait for the hearing to end on Monday, It occurred to me whether there have been any articles, from the research, about the NGAL test, that could detect, at an earlier stage, that their kidney is damaged. ( That was their working title ) I found the scientific article that describes what the researchers found out. One can read in the article that the researchers had positive results, and that it looked as if the NGAL test, at an early stage, could detect if the kidney was damaged. When KDIGO comes with their recommendations, and if they include this group, as a 1st degree recommendation, then the test will become a permanent part of the treatment offer. See below, conclusions. https://www.sciencedirect.com/science/article/pii/S1056872725000558
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 295 004 | 295 004 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 295 004 | 295 004 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
43 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenI'm out right now - I don't believe in KDIGO in this round. I cannot imagine that one creates best practice for a product that is not approved for adults, but only for children! I believe conservatism will prevail in this round.·4 t sittenKDIGO has some guidelines now. Hospitals treat according to them, and insurance companies compensate. If Ngal is to be included, then I find it hard to see KDIGO moving to a place where there is no evidence! And evidence will probably only come in the adult area when companies deliver studies that FDA approves based on. That's probably what BioPorto is doing - honestly! And still...: If insurance companies are to pay up, then they will probably lean on products that are approved?! An unapproved product probably doesn't have much weight in relation to insurance companies? KDIGO or not! Regards, Bagerbrød·4 t sittenI have spent hours trying to make sense of KDIGO. I have shared everything further down. If I am right that it becomes a 1st degree recommendation in crisis areas, then all hospitals, including in the USA, will ensure that the NGAL test becomes a permanent part of routine treatments in affected areas. If hospitals in the USA do not introduce the NGAL test where there is a 1st degree recommendation, and deaths occur at this hospital, then they risk being sued by relatives because they did not use the NGAL test, according to KDIGO's recommendations. What the FDA might do, regarding the NGAL test, for adults, after a 1st degree recommendation, and they have not yet approved the test, is to give it emergency use authorization status, while the FDA is in the process of their procedure. With a 2nd degree recommendation, it is up to the doctor's assessment whether they want the NGAL test in their routine treatment.
- 9 t sitten9 t sitten"Initiating coverage with a fair value of DKK 0.5–3.0 per share. The upper end reflects an additional 10% revenue growth and 1% annual margin expansion for the explicit forecast period, while the low end reflects a failure of ProNephro FDA approval for adults." Fra DNB Carnegies omfattende og gennemarbejdede 50 siders analyse, som udkom for knap en måned siden.
- ·10 t sittenOn Monday the hearing ends, and then I will keep an eye on whether Paul Palevsky and/or Marlies Ostermann come out and brief the doctors and other good people about what is being discussed in KDIGO's committee, and what they are leaning towards and whether they are reaching an agreement, or are far apart. I think it's a loooong time until Monday.
- ·3 päivää sitten3D missen can you explain to me why you think this one is so interesting I am very curious good luck·2 päivää sittenI can't remember it exactly, but I was involved when they were still at the research level. four years maybe. why that?·2 päivää sittenNgal has been on the market for approx. 15 years and frankly, Bioporto is still in a form of "research level" and start-up in 2026 without a shadow of PROC.
- ·4.5.It was just going the right way, and now it's plummeting today??·4.5. · MuokattuWhile I wait for the hearing to end on Monday, It occurred to me whether there have been any articles, from the research, about the NGAL test, that could detect, at an earlier stage, that their kidney is damaged. ( That was their working title ) I found the scientific article that describes what the researchers found out. One can read in the article that the researchers had positive results, and that it looked as if the NGAL test, at an early stage, could detect if the kidney was damaged. When KDIGO comes with their recommendations, and if they include this group, as a 1st degree recommendation, then the test will become a permanent part of the treatment offer. See below, conclusions. https://www.sciencedirect.com/science/article/pii/S1056872725000558
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 598 | - | - | ||
| 12 526 | - | - | ||
| 7 000 | - | - | ||
| 69 | - | - | ||
| 1 131 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 295 004 | 295 004 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 295 004 | 295 004 | 0 | 0 |